Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7249-7259.
-
Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.
-
Benjamin WJ, Feng AL, Heft Neal M, Bellile E, Casper KA, Malloy KM, Rosko AJ, Stucken CL, Prince ME, Mierzwa ML, Taylor JMG, Eisbruch A, Spector ME, Wolf GT, Swiecicki PL, Worden FP, Chinn SB. Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer. Oral Oncol. 2024 Sep; 156:106917.
-
Bhardwaj PV, Mason H, Kaufman SA, Visintainer P, Makari-Judson G. Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center. Curr Oncol. 2023 05 08; 30(5):4861-4870.
-
Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, Chen N, Hahn O, Fleming G, Huo D, Nanda R. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
-
Ersoy E, Elsayad M, Pandiri M, Knee A, Cao QJ, Crisi GM. Intraoperative Lymph Node Assessment (Touch Preparation Only) for Metastatic Breast Carcinoma in Neoadjuvant and Non-neoadjuvant Settings. Arch Pathol Lab Med. 2023 02 01; 147(2):149-158.
-
Atukorale PU, Moon TJ, Bokatch AR, Lusi CF, Routhier JT, Deng VJ, Karathanasis E. Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers. Nanoscale. 2022 Jan 27; 14(4):1144-1159.
-
Karakasheva TA, Gabre JT, Sachdeva UM, Cruz-Acu?a R, Lin EW, DeMarshall M, Falk GW, Ginsberg GG, Yang Z, Kim MM, Diffenderfer ES, Pitarresi JR, Li J, Muir AB, Hamilton KE, Nakagawa H, Bass AJ, Rustgi AK. Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer. Sci Rep. 2021 10 29; 11(1):21304.
-
Liu S, Bellile E, Nguyen A, Zarins K, D'Silva N, Rozek L, Wolf GT, Sartor MA. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncol. 2021 12; 123:105587.
-
Peponis T, Stafford C, Cusack J, Cauley C, Goldstone R, Berger D, Parikh A, Bordeianou L, Kunitake H, Francone T, Ricciardi R. The Use of Single-Agent Versus Multiple-Agent Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer. J Gastrointest Cancer. 2022 Sep; 53(3):557-563.